Zimmer Biomet (NYSE:ZBH) Sets New 12-Month Low – Should You Sell?

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $97.69 and last traded at $98.98, with a volume of 2496731 shares trading hands. The stock had previously closed at $98.98.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ZBH. Wells Fargo & Company increased their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Barclays reduced their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Royal Bank of Canada cut their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Stock Performance

The stock has a market cap of $19.70 billion, a P/E ratio of 22.24, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43. The stock has a 50 day simple moving average of $106.91 and a 200 day simple moving average of $107.91.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the company earned $2.20 earnings per share. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.97%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. CWM LLC increased its position in Zimmer Biomet by 7.4% during the 3rd quarter. CWM LLC now owns 6,966 shares of the medical equipment provider’s stock worth $752,000 after purchasing an additional 481 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Zimmer Biomet by 3,043.1% during the third quarter. Exchange Traded Concepts LLC now owns 1,603 shares of the medical equipment provider’s stock worth $173,000 after buying an additional 1,552 shares in the last quarter. CX Institutional acquired a new position in shares of Zimmer Biomet during the third quarter worth $93,000. Wesbanco Bank Inc. lifted its stake in shares of Zimmer Biomet by 2.5% in the 3rd quarter. Wesbanco Bank Inc. now owns 20,411 shares of the medical equipment provider’s stock valued at $2,203,000 after acquiring an additional 489 shares during the last quarter. Finally, NBC Securities Inc. acquired a new stake in shares of Zimmer Biomet during the 3rd quarter valued at $105,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.